Literature DB >> 36068448

A research review of experimental animal models with myelodysplastic syndrome.

Gen-Wang Chen1, Mei-Na Chen2, Lei Liu1, Yu-Yu Zheng1, Jin-Peng Wang1, Si-Si Gong1, Rong-Fu Huang1, Chun-Mei Fan3, Yue-Zu Chen2.   

Abstract

Myelodysplastic syndrome (MDS) consists of a group of hematologic tumors that are derived from the clonal proliferation of hematopoietic stem cells, featuring abnormal hematopoietic cell development and ineffective hematopoiesis. Animal models are an important scientific research platform that has been widely applied in the research of human diseases, especially tumors. Animal models with MDS can simulate characteristic human genetic variations and tumor phenotypes. They also provide a reliable platform for the exploration of the pathogenesis and diagnostic markers of MDS as well as for a drug efficacy evaluation. This paper reviews the research status of three animal models and a new spontaneous mouse model with MDS.
© 2022. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).

Entities:  

Keywords:  Animal model; Myelodysplastic syndrome (MDS); Spontaneous MDS model

Year:  2022        PMID: 36068448     DOI: 10.1007/s12094-022-02931-7

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.340


  41 in total

Review 1.  Mouse models of myelodysplastic syndromes.

Authors:  Sarah H Beachy; Peter D Aplan
Journal:  Hematol Oncol Clin North Am       Date:  2010-04       Impact factor: 3.722

Review 2.  EVI1 and hematopoietic disorders: history and perspectives.

Authors:  Giuseppina Nucifora; Leopoldo Laricchia-Robbio; Vitalyi Senyuk
Journal:  Gene       Date:  2005-11-28       Impact factor: 3.688

Review 3.  Molecular, cytogenetic and genetic abnormalities in MDS and secondary AML.

Authors:  R A Padua; A McGlynn; H McGlynn
Journal:  Cancer Treat Res       Date:  2001

4.  De Novo myelodysplastic syndromes in patients 20-50 years old are enriched for adverse risk features.

Authors:  Zachary D Epstein-Peterson; Barbara Spitzer; Andriy Derkach; Juan E Arango; Joseph G W McCarter; Juan S Medina-Martínez; Erin McGovern; Noushin Rahnamay Farnoud; Ross L Levine; Martin S Tallman
Journal:  Leuk Res       Date:  2022-05-10       Impact factor: 3.156

5.  Therapy-related leukemia and myelodysplasia: susceptibility and incidence.

Authors:  Giuseppe Leone; Livio Pagano; Dina Ben-Yehuda; Maria Teresa Voso
Journal:  Haematologica       Date:  2007-10       Impact factor: 9.941

6.  Proapoptotic BID is required for myeloid homeostasis and tumor suppression.

Authors:  Sandra S Zinkel; Christy C Ong; David O Ferguson; Hiromi Iwasaki; Koichi Akashi; Roderick T Bronson; Jeffery L Kutok; Frederick W Alt; Stanley J Korsmeyer
Journal:  Genes Dev       Date:  2003-01-15       Impact factor: 11.361

7.  EVI1 induces myelodysplastic syndrome in mice.

Authors:  Silvia Buonamici; Donglan Li; Yiqing Chi; Rui Zhao; Xuerong Wang; Larry Brace; Hongyu Ni; Yogen Saunthararajah; Giuseppina Nucifora
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

8.  Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression.

Authors:  Azra Raza; Silvia Buonamici; Laurie Lisak; Sarah Tahir; Donglan Li; Mehnaz Imran; Nusrat Ijaz Chaudary; Hassan Pervaiz; J Alejandro Gallegos; M Imran Alvi; Muhammad Mumtaz; Sefer Gezer; Parameswaran Venugopal; Poluru Reddy; Naomi Galili; Anna Candoni; Jack Singer; Giuseppina Nucifora
Journal:  Leuk Res       Date:  2004-08       Impact factor: 3.156

9.  EVI1 Impairs myelopoiesis by deregulation of PU.1 function.

Authors:  Leopoldo Laricchia-Robbio; Kavitha Premanand; Ciro R Rinaldi; Giuseppina Nucifora
Journal:  Cancer Res       Date:  2009-02-10       Impact factor: 12.701

10.  Benzene exposure--an experimental machinery for induction of myelodysplastic syndrome: stem cell and stem cell niche analysis in the bone marrow.

Authors:  Madhurima Das; Samaresh Chaudhuri; Sujata Law
Journal:  J Stem Cells       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.